MOMENTUM Trial Outcomes: Guiding Therapy for Myelofibrosis With Anemia and Splenomegaly
Panelists discuss how the MOMENTUM trial demonstrated momelotinib’s superiority over danazol in symptomatic anemic myelofibrosis patients, showing significant improvements in symptoms (the primary end point), meaningful spleen volume reduction (SVR25/SVR35), and anemia benefits, with experts noting that the inclusion of a washout period provided clearer evidence of momelotinib’s efficacy profile compared to the SIMPLIFY-2 trial.
Summary of MOMENTUM Trial: Momelotinib in Anemic, Symptomatic Myelofibrosis
Study Design and Population
- Patient characteristics:
- Required hemoglobin <10 g/dL
- Symptomatic disease
- Previously treated with Janus kinase (JAK) inhibitor therapy
- Design elements:
- Primary end point was symptom-driven
- Active comparator arm (danazol) rather than placebo
- Included a washout period (unlike SIMPLIFY-2)
Key Findings
- Primary end point:
- Momelotinib demonstrated superior symptom benefits compared to danazol
- Secondary end points:
- Multiple secondary end points met with superiority
- Stronger spleen volume reduction data (SVR25, SVR35) than in SIMPLIFY-2
- Confirmed anemia benefits
Clinical Implications
- Comprehensive benefit profile:
- Triple benefit: spleen reduction, symptom improvement, and anemia benefits
- Washout period may have contributed to clearer demonstration of spleen benefits compared to SIMPLIFY-2
- Clinician perspective:
- Some practitioners noted less direct relevance of danazol comparison in their practice
- Nevertheless, provided further evidence of momelotinib’s anemia benefit
- Results support momelotinib use in patients with anemic, symptomatic myelofibrosis who have received prior JAK inhibitor therapy
The MOMENTUM trial reinforces momelotinib’s position in the treatment algorithm, particularly for patients with anemia who have been previously treated with other JAK inhibitors.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
